Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
OnMed Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
OnMed has been named to Fast Company’s World’s Most Innovative Companies list for 2026, earning a No. 14 ranking in North America. The company’s AI‑enabled CareStation™ platform has expanded into rural states, schools, an airport hub, and Puerto Rico over the past 18 months. Recent milestones include a CES debut, multiple industry awards and high‑impact public‑private partnerships. The recognition places OnMed alongside tech giants such as Google and Nvidia, underscoring its disruptive hybrid‑healthcare model.
It’s Not ‘Racism’, It’s Statistics…
CVS has begun locking darker foundation and concealer shades behind anti‑theft devices, citing shoplifting data rather than racial intent. Retail theft in the U.S. surged 19 percent year‑over‑year, with projected losses near $48 billion for 2026, prompting chains to protect high‑risk items....
Seven‑Domain Framework Elevates Person‑Centered Longevity Care
The Longevity Medicine Patient Experience Framework: A Seven-Domain Model for Optimizing Person-Centered Longevity Medicine "By operationalizing a patient-experienced, person-centered approach, this framework offers potential solutions to common challenges in longevity medicine, including care fragmentation, accessibility barriers, and poor patient engagement. It...
Experts Urge Balanced Diets to Boost GLP‑1 Anti‑Obesity Drug Benefits
Nutritionists and obesity physicians say GLP‑1 drugs such as Wegovy and Zepbound only deliver lasting weight loss when paired with a high‑protein, high‑fiber, well‑hydrated diet. With roughly one in eight U.S. adults on these medicines and more than 600,000 Wegovy‑pill...
STAT+: Pharmalittle: We’re Reading About a Trump Drug Pricing Flaw, a Gilead Deal, and More
A senior Trump administration health official warned that the president’s most‑favored‑nation (MFN) drug‑pricing strategy may unintentionally raise prices abroad rather than lower them in the United States. The flaw arises because manufacturers could postpone launching new drugs in foreign markets,...
Cerebral Acquires Cognitive Behavioral Therapy App Inflow to Expand ADHD Treatment
Cerebral, a large integrated mental‑health provider, has acquired Inflow, a CBT‑based digital therapeutic app for adult ADHD, though financial terms were not disclosed. Inflow delivers short, science‑backed daily modules and is supported by an eight‑week randomized controlled trial showing significant...
Digital Tech Redefines Pharma Manufacturing and Distribution
This book explains how disruptive technologies and emerging trends such as robotics, artificial intelligence, 3D printing, precision medicine or patient design will impact the manufacturing and distribution of pharmaceuticals in order to prepare successfully for a better future of healthcare. Everything...
Ibogaine Could Save Veterans, Despite U.S. Ban
Teared up watching In Waves and War last night. Every day ~20 vets commit suic*de. Heartbreaking. The doc showcases ibogaine’s massively positive benefits for three troubled navy seals. Unfortunately it’s illegal in the US but ketamine isn’t and has had similar...
Regulators Inspect 49 Companies Over Unauthorized Weight‑Loss Drug Sales
Regulatory agencies have launched inspections of 49 firms suspected of distributing unauthorized weight‑loss drugs. The sweep underscores heightened scrutiny of the booming weight‑loss market and raises questions about compliance across the industry.
The Scrapers At MyChart's Gate
Fan Pier Labs released an open‑source MyChart connector that automates login, 2FA, and exposes 35+ tools to read and write patient data via the web UI. Unlike official FHIR APIs, it can perform any action a patient can, including messaging providers and...
Seattle Clinic’s 16‑Week Tech‑Addiction Detox Treated Like Substance Abuse
Seattle‑area clinic reSTART has opened a 16‑week residential detox program that treats technology overuse as a substance‑use disorder. The intensive regimen forces participants to abstain from internet, smartphones, gaming and other digital media, positioning the service at the forefront of...
ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners
ImmuneBridge announced a $7.7 million second seed round, bringing its total seed capital to roughly $20 million, to commercialize its proprietary cell‑therapy screening and manufacturing platform for external partners. The platform combines machine‑learning‑driven donor selection with a unique small‑molecule that preserves stem‑cell...
Dual-Action Antiviral Treatments Offer A New Path Forward
Scientists at the U.S. Army Medical Research Institute of Infectious Diseases have engineered a dual‑action antibody that simultaneously targets two stages of Venezuelan equine encephalitis virus (VEEV) entry. The single‑molecule treatment protected animals even when given after exposure and neutralized...
XO Health to Expand Its Alternative Health Plan Nationwide
XO Health, a startup that provides an alternative health plan, announced a nationwide rollout targeting self‑insured employers and plan administrators. The company will extend its episode‑based pricing model, which bundles all services for a specific medical episode into a single,...
Celosia Therapeutics Starts First‑Human Dosing of CTx1000 Gene Therapy for ALS
Celosia Therapeutics has dosed the first participant in its Phase 1b KOANEWA trial of CTx1000, a gene‑editing medicine that clears pathological TDP‑43 protein in ALS patients. The open‑label study, run at Macquarie University Hospital, marks the first human test of...
Experian Health’s 2026 State of Patient Access Survey Reveals Patient Experience Is Improving, but Big Challenges Remain for Healthcare Providers
Experian Health’s 2026 State of Patient Access Survey shows modest gains in perceived access, with 46% of providers saying access improved versus only 18% of patients. Operational efficiencies and digital tools are helping, but staffing shortages now affect 64% of...
Viz.ai and Alnylam Pharmaceuticals Partner to Launch AI Care Pathway for Cardiac Amyloidosis
Viz.ai and Alnylam Pharmaceuticals have teamed up to launch an AI‑driven care pathway targeting cardiac amyloidosis, a frequently underdiagnosed heart disease. The solution embeds the FDA‑cleared Us2.ai echocardiography algorithm and generative AI into hospital IT systems to automatically detect subtle...
Leica Biosystems Launches Aperio GT Elite Scanner, Aperio iQC Software
Leica Biosystems, a Danaher company, launched the Aperio GT Elite digital pathology scanner in the U.S., paired with Aperio iQC software featuring AI‑driven rescan capabilities. The scanner can process up to 103 slides per hour, scanning a slide in as...
Imaging Agent Granted FDA Fast Track Designation
FluoGuide A/S announced that the U.S. FDA has granted Fast Track designation to its intraoperative imaging agent FG001, targeting high‑grade glioma surgery. The designation recognizes the serious nature of glioblastoma and the agent's promise to improve tumor visualization during resection....
New AD Combos Outpace Dupilumab, Injection Frequency Drops
Atopic dermatitis landscape from Wedbush. Looks like there are two parallel vectors: lower injection frequency ( $APGE ) and combining new mechanisms with IL13/IL4R. So far $JNJ's IL13+IL31 failed (the only one to be directly compared to dupi) while $PFE's...
The Displaced Valve: Recognizing Ebstein's Anomaly on Echo
Ebstein's anomaly is a congenital malformation where the tricuspid valve remains tethered to the ventricular wall, causing apical displacement. The condition may be identified at birth or remain silent until adulthood, often presenting as right‑heart remodeling on imaging. Echocardiography is...
THE IMPACT OF ARTIFICIAL INTELLIGENCE ON PHARMACEUTICAL AND LIFESCIENCES INDUSTRY
Artificial intelligence is reshaping the pharmaceutical and life‑sciences value chain, from molecule discovery with generative and structure‑prediction models to clinical trial design, manufacturing, regulatory submissions, intellectual property and supply‑chain orchestration. Tools such as AlphaFold and de‑novo design engines accelerate lead...
3.1 Million Impacted by QualDerm Data Breach
QualDerm Partners disclosed that a December 2025 cyber‑attack compromised the personal, medical, and health‑insurance records of more than 3.1 million individuals. Attackers accessed the network for two days, exfiltrating data from a limited set of systems before the breach was detected...
Fatty Liver Breakthrough: A Common Vitamin Shows Promise
Researchers at UNIST and partner institutions identified microRNA‑93 as a central driver of metabolic‑associated fatty liver disease (MASLD) and demonstrated that vitamin B3 (niacin) can suppress this molecule, restoring SIRT1 activity and reducing liver fat in mice. The study, published in...
Menstrual Hormones May Worsen ADHD Symptoms in Medicated Women
A pilot study of thirty adult women with ADHD who take amphetamine‑based stimulants found that symptom severity and negative mood spike during the menstrual phase, while mid‑follicular days show milder symptoms. Daily medication dosages remained unchanged across the cycle, indicating...
Biotech Investors Set to Meet with Key Congressional Panel
A bipartisan congressional commission focused on maintaining U.S. leadership in biotechnology will host a meeting with leading biotech investors next week. The investors, representing venture capital firms and industry funds, aim to discuss policy gaps, funding mechanisms, and regulatory hurdles....
Beyond AI: How 3D Surgical Intelligence Is Expanding Radiology’s Clinical Impact
Radiology is extending its diagnostic role by delivering patient‑specific 3D surface models that surgeons can manipulate for pre‑operative planning. Studies show these digital models reduce operating‑room time, lower complication rates, and improve surgical predictability across orthopedics, oncology, and reconstructive procedures....
How Far Has AM in Healthcare Really Come? Find Out at RAPID + TCT 2026
The RAPID + TCT 2026 Healthcare Conference track highlighted how additive manufacturing (AM) is moving from theoretical potential to concrete production in medicine. Speakers covered scaling custom orthotics through standardized workflows, navigating FDA‑driven documentation via OEM collaborations, and using bioprinting to create...
How Potentially Unwanted Programs Affect Healthcare Data Privacy and Compliance
Healthcare’s rapid digitization has expanded electronic health records, cloud services, and connected devices, but it also widens the attack surface for potentially unwanted programs (PUPs). These low‑profile applications often arrive through bundled installers or browser extensions, silently collecting and transmitting...
Prestige Biopharma Reports Topline P-III (SAMSON-II) Study Results for HD204 (Biosimilar, Avastin)
Prestige Biopharma announced topline results from its phase‑III SAMSON‑II trial comparing HD204, a biosimilar to Avastin (bevacizumab), with the reference product in 625 patients with advanced non‑squamous non‑small cell lung cancer. The study demonstrated an objective response rate (ORR) of...
Apnimed Set to Exit Sleep Disorder Joint Venture with Shionogi for $100M Upfront
Japanese pharmaceutical company Shionogi is buying out Apnimed’s 50% stake in their sleep‑disorder joint venture for an upfront payment of $100 million. The acquisition gives Shionogi full control over the partnership’s pipeline, which focuses on treatments for conditions such as obstructive...
‘Warcraft… with Pure Thought Control’ — 100 Days with Neuralink ‘Feels Like Science Fiction’ to Early Brain Chip Pioneer
British Army veteran Jon Noble has spent 100 days with Neuralink’s N1 brain‑computer interface implanted in his motor cortex, allowing him to play World of Warcraft using only thought. The implant translates neural activity into digital commands, letting him navigate...
3 Potential Policy Options for High-Acuity Palliative Services
The Medicare Payment Advisory Commission (MedPAC) is reviewing three payment pathways—outlier payments, guaranteed add‑on payments, and a case‑mix adjustment—to broaden Medicare hospice coverage of high‑acuity palliative services such as radiation, chemotherapy, dialysis and blood transfusions. These treatments are often withheld...
New Research on 3D Printed Heart Attack Sensing Platform With 17 Cents Electrodes
Researchers at the University of Brighton and the University of Strathclyde have created a fully 3D‑printed electrochemical sensor that detects the heart‑attack biomarker cardiac troponin I at 7.4 pg/mL in undiluted human serum. The electrodes, printed on a desktop FlashForge Creator Pro 2 using...
Reforms to GMC to Simplify Striking Off Discriminatory Doctors
Labour health secretary Wes Streeting announced reforms to give the General Medical Council (GMC) stronger powers to discipline doctors who use racist or discriminatory language. The changes would allow the GMC to challenge and overturn decisions of the Medical Practitioners...
GLP‑1 Weight Loss Risks Muscle Loss without Proper Monitoring
We are prescribing powerful weight loss drugs without measuring the most important metric: muscle mass. Physical therapist Maureen McBeth has tested the body composition of countless patients who lost 50 pounds on GLP-1s. The results? Dangerously low skeletal muscle and exceptionally...
WHO Issues Three Recommendations for Responsible AI in Mental Health
The World Health Organization unveiled three recommendations for responsible AI deployment in mental health and wellbeing, calling for public‑health framing, integrated impact assessments, and co‑design with experts. The guidance, produced after a workshop of 30+ international specialists, also announces a...
FDA Clears 7.2 Mg Wegovy HD, Boosting Weight‑Loss Potential by 19%
The U.S. Food and Drug Administration approved a 7.2‑milligram version of Novo Nordisk’s semaglutide weight‑loss drug Wegovy, dubbed Wegovy HD. Clinical data showed participants lost roughly 19% of body weight, about 47 pounds on average, compared with 16% on the...
Gubra‑AbbVie’s ABBV-295 Achieves Up to 9.8% Weight Loss in Early Trial
Gubra and AbbVie announced that participants in a Phase 1 multiple‑ascending‑dose study of ABBV-295 lost between 7.8% and 9.8% of their body weight after roughly three months. The amylin analog was well tolerated, positioning it as a potential new class of...
Regulators Tighten Grip on Weight‑Loss Drugs and Medical Devices Amid Rising Enforcement Actions
India's high court cleared Dr Reddys to produce the weight‑loss drug semaglutide, unlocking a billion‑dollar market, as health regulators in Ireland recalled 18,000 Philips Respironics machines over foam degradation. The twin moves underscore mounting compliance pressure across the pharma and...
Seattle's reSTART Clinic Treats Tech Overuse as Substance Abuse in 16‑Week Detox
reSTART, a residential treatment center outside Seattle, is prescribing 16‑week, screen‑free detox programs for technology addiction, equating it with drug dependence. The model arrives as high‑profile lawsuits against Meta, YouTube and other platforms push the legal definition of "tech addiction"...
Inulin Cuts Knee OA Pain, Boosts Sensitivity and Strength
Effect of Prebiotic Supplementation With and Without Physiotherapy on Pain and Pain Sensitivity in People with Knee Osteoarthritis "Inulin and PSE each produced meaningful pain reductions. Only inulin improved pain sensitivity and grip strength, the latter paralleled by increased GLP-1, and...
FDA Job Posting Omits Vaccine Requirement, Sparks Speculation
The Readout newsletter contained this nugget today. The posting for Vinay Prasad's job at #FDA states applicants don't need to be vaccinated. USG job postings don't normally address vaccination status. Message to the MAHA base? Sign up for @statnews newsletters here: https://t.co/Q3BKEkVZs0
Japan to Cut All Out‑of‑Pocket Childbirth Costs Under Expanded Health Insurance
Japan’s cabinet approved an expansion of public health insurance that will eliminate patient cost‑sharing for childbirth, standardizing delivery fees and covering them entirely. The move targets a birth rate that slipped below 710,000 in 2025 despite more than $20 billion in...
Former Acorda CEO Joins Parkinson’s Cell Therapy Startup
How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup https://t.co/93JYvJGM9I by @realJacobBell #biotech #startups
How Trump Is Trying to Make 'Fraud' The New DOGE
President Trump has turned fraud into a political rallying cry, using unverified claims that Minnesota’s Medicaid program lost $19 billion to justify withholding $259 million in federal funds. The administration’s new executive order creates a fraud task force that focuses on blue‑state...
Chronic Medical Conditions Predict Childhood Depression More Strongly than Social or Family Hardships
A new analysis of the 2022‑2023 National Survey of Children’s Health, covering 65,652 U.S. youths, finds that chronic medical conditions are the strongest predictor of childhood depression, outpacing poverty or parental divorce. Each additional medical health risk nearly doubles the...
Gilead to Pay $1.68 B Upfront for Ouro Medicines, Adding T‑cell Engager to Autoimmune Portfolio
Gilead Sciences signed a definitive agreement to acquire privately held Ouro Medicines for $1.675 billion in cash up front and up to $500 million in milestone payments, targeting the experimental T‑cell‑engaging antibody OM336. The deal, valued at up to $2.18 billion, gives Gilead...